Vaccination In People With Long COVID

This study aims to determine the effects of vaccination against SARS-CoV-2 in people with long COVID


The Sociedad Española de Médicos Generales y de Familia (SEMG) and the collective of affected people @longcovidACTS have been working together for months to try to provide answers to those affected by Persistent or Long COVID.

Now they want to go a step further and want to know what the situation is regarding vaccination against SARS-CoV-2 when suffering from Persistent COVID or Long COVID.

Description of the Study:

  • Title: Study of the effects of vaccination in people with persistent COVID.
  • Principal Investigators: Sociedad Española de Médicos Generales y de Familia (SEMG) and the LONG COVID ACTS alliance of regional groups.
  • Study Population: Individuals who:
    – Have persistent COVID or Long COVID, i.e. they have had COVID-19 and their symptoms persist beyond 4 weeks, and in addition.
    – Have had two doses of SARS-CoV-2 vaccine, or have had one dose and are not going to have a second dose.
  • Study Type: Observational study.
  • Design: A survey will identify how the vaccine affects their symptomatology, i.e. which patients with persistent COVID could benefit from vaccination and which could not, or whether the effect varies with the type of vaccine administered.
  • Methods: Anonymised form, which takes about five minutes to complete and does not require any personal identification data, for the collection of information in relation to COVID-19 vaccination.

Objectives of the Study:

Principal Objective: To follow up the effect of vaccination against SARS-CoV-2 in patients who have had COVID-19 and their symptoms persist over time beyond 4 weeks, i.e. patients with persistence of COVID-19 symptoms.

More about this Study:

Scientific Context: The increase in COVID-19 infections has made the existence of so-called persistent COVID-19 or “long COVID-19” increasingly evident. This is the name given to cases where the infected patient has symptoms beyond the approximately 14 days that are considered normal for COVID-19 cases. Although sometimes referred to as sequelae, these are actually symptoms: patients with persistent COVID-19 may experience symptoms four weeks or even months after infection. Symptoms may include coughing, hair loss, fatigue or chest pain.

Logosemg


Other Epidemiological Studies:

Effectiveness of vaccine combination

Científicos franceses demuestran que la vacunación primaria con dos vacunas diferentes sería más eficaz que la vacunación con dos vacunas idénticas.

The Social Perception Of COVID-19 Vaccines

This study conducted by the UOC aims to find out the opinion of the Spanish population and professional healthcare personnel on the COVID-19 vaccines.

CombivacS

Clinical trial designed to evaluate the safety and immunogenicity of a dose of Comirnaty vaccine (Pfizer) in people who have previously received a dose of Vaxcevria vaccine (AstraZeneca).

MOOD-COVID

MOOD-COVID aims to study the impact of the pandemic on the mental health of pregnant women, young mothers and their children.

Emotional State Of Adults In The Process Of Bereavement By COVID-19

This study aims to analyse the emotional and spiritual state of adults who have lost a loved one due to COVID-19.

E-speranza-COVID19 Project

This study aims to demonstrate efficacy of Montelukast for patients with persistent COVID-19 to help them improve their quality of life.

Early Corticosteroid Treatment for COVID-19

This study proposal aims to determine whether early corticosteroid treatment can reduce the need for oxygen therapy and post-COVID sequelae.

MINDCOVID: Mental Health in a Pandemic

This study aims to assess the mental health impact and needs associated with COVID-19 in Spain.

CIBERESUCI COVID

CIBERES UCI COVID is a fundamental study that will improve care of critical patients infected by COVID-19.

NAUTILUS Project

The NAUTILUS project aims to develop an artificial intelligence platform to identify, predict and intervene on persistent symptoms in people who have suffered from COVID-19.